Электронная медицинская библиотека Румедо.

Статьи

Алгоритмы специализированной медицинской помощи больным сахарным диабетом (8-й выпуск)

Дата публикации 22.10.2020
Под редакцией: И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова

Данное издание содержит девятый актуализированный выпуск (дополненный) клинических рекомендаций по стандартизации и оптимизации оказания медицинской помощи больным сахарным диабетом во всех регионах России на основе доказательной медицины.

Подробнее

1006

Зарубежные материалы

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Дата публикации 22.10.2020
Автор: Bruce Neal, M.B., Ch.B., Ph.D., Vlado Perkovic, M.B., B.S., Ph.D., Kenneth W. Mahaffey, M.D., Dick de Zeeuw, M.D., Ph.D., Greg Fulcher, M.D., Ngozi Erondu, M.D., Ph.D., Wayne Shaw, D.S.L., Gordon Law, Ph.D., Mehul Desai, M.D., and David R. Matthews, D.Phil., B.M., B.Ch., for the CANVAS Program Collaborative Group

Canagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes.

Подробнее

914

Статьи

ЭКГ высокого разрешения в выборе антигипертензивной терапии у больных сахарным диабетом

Дата публикации 22.10.2020
Автор: Шурдумова Марьяна Газалиевна, кандидат медицинских наук, старший преподаватель кафедры нормальной и патологической физиологии медицинского факультета, ФГБОУ ВПО «КабардиноБалкарский государственный университет им. Х.М. Бербекова» Минобрнауки России, КабардиноБалкарская Республика

Изучена прогностическая значимость ЭКГ высокого разрешения у больных сахарным диабетом, получавших моноприл и небиволол. Обследовано 138 больных сахарным диабетом с артериальной гипертензией и 60 больных сахарным диабетом без артериальной гипертензии путем анализа поздних потенциалов желудочков, проведен сравнительный анализ с больными, получавшими моноприл и небилет.

Подробнее

718

Зарубежные материалы

Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

Дата публикации 22.10.2020
Автор: Iciar Martín-Timón, Cristina Sevillano-Collantes, Amparo Segura-Galindo, Francisco Javier del Cañizo-Gómez

Diabetes mellitus is a chronic condition that occurs when the body cannot produce enough or effectively use of insulin. Compared with individuals without diabetes, patients with type 2 diabetes mellitus have a considerably higher risk of cardiovascular morbidity and mortality, and are disproportionately affected by cardiovascular disease.

Подробнее

958

Зарубежные материалы

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetesd2019

Дата публикации 22.10.2020
Автор: American Diabetes Association

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care.

Подробнее

1203

Зарубежные материалы

National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification

Дата публикации 22.10.2020
Автор: Andrew S. Levey, MD; Josef Coresh, MD, PhD; Ethan Balk, MD, MPH; Annamaria T. Kausz, MD, MS; Adeera Levin, MD; Michael W. Steffes, MD, PhD; Ronald J. Hogg, MD; Ronald D. Perrone, MD; Joseph Lau, MD; and Garabed Eknoyan, MD

Chronic kidney disease is a worldwide public health problem with an increasing incidence and prevalence, poor outcomes, and high cost. Outcomes of chronic kidney disease include not only kidney failure but also complications of decreased kidney function and cardiovascular disease.

Подробнее

850

Зарубежные материалы

Cardiorenal Syndrome

Дата публикации 22.10.2020
Автор: Claudio Ronco, MD, Mikko Haapio, MD, Andrew A. House, MSC, MD, Nagesh Anavekar, MD, Rinaldo Bellomo, MD

The term cardiorenal syndrome (CRS) increasingly has been used without a consistent or well-accepted definition. To include the vast array of interrelated derangements, and to stress the bidirectional nature of heartkidney interactions, we present a new classification of the CRS with 5 subtypes that reflect the pathophysiology, the time-frame, and the nature of concomitant cardiac and renal dysfun ...

Подробнее

910

Зарубежные материалы

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

Дата публикации 22.10.2020
Автор: E.A. Bohula, S.D. Wiviott, D.K. McGuire, S.E. Inzucchi, J. Kuder, K.A. Im, C.L. Fanola, A. Qamar, C. Brown, A. Budaj, A. Garcia‑Castillo, M. Gupta, L.A. Leiter, N.J. Weissman, H.D. White, T. Patel, B. Francis, W. Miao, C. Perdomo, S. Dhadda, M.P. Bonaca, C.T. Ruff, A.C. Keech, S.R. Smith, M.S. Sabatine, and B.M. Scirica, for the CAMELLIA–TIMI 61 Steering Committee and Investigators

Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined.

Подробнее

797

Зарубежные материалы

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

Дата публикации 22.10.2020
Автор: SILVIO E. INZUCCHI, MD1 RICHARD M. BERGENSTAL, MD2 JOHN B. BUSE, MD, PHD3 MICHAELA DIAMANT, MD, PHD4 ELE FERRANNINI, MD5 MICHAEL NAUCK, MD6 ANNE L. PETERS, MD7 APOSTOLOS TSAPAS, MD, PHD8 RICHARD WENDER, MD9 DAVID R. MATTHEWS, MD, DPHIL10,

Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Подробнее

921

Зарубежные материалы

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Дата публикации 22.10.2020
Автор: Eri T. Kato, MD, MPH, PhD et al

In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) ...

Подробнее

887

Статьи

Карманные рекомендации для врачей по ведению пациентов с сахарным диабетом и ожирением

Дата публикации 22.10.2020
Под редакцией: М.В. Шестаковой, академика РАН, д.м.н., проф., директора Института диабета, заместителя директора ФГБУ «Эндокринологический научный центр» по научной работе.

Специализированное издание, предназначенное для медицинских и фармацевтических работников

Подробнее

780

Зарубежные материалы

Obesity and Diabetic Kidney Disease

Дата публикации 22.10.2020
Автор: Christine Maric-Bilkan, PhD. Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA

The prevalence of obesity (body mass index, BMI ≥ 30 kg/m2) has risen to epidemic proportions and continues to be a major health problem worldwide 1–3. The high prevalence of obesity is closely linked to the increased incidence of a number of chronic diseases, including type 2 diabetes, hypertension and cardiovascular disease 2, 4–8.

Подробнее

1148

Зарубежные материалы

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (HHS Public Access)

Дата публикации 22.10.2020
Автор: Steven P. Marso, M.D., Gilbert H. Daniels, M.D., Kirstine Brown-Frandsen, M.D., Peter Kristensen, M.D., E.M.B.A., Johannes F.E. Mann, M.D., Michael A. Nauck, M.D., Steven E. Nissen, M.D., Stuart Pocock, Ph.D., Neil R. Poulter, F.Med.Sci., Lasse S. Ravn, M.D., Ph.D., William M. Steinberg, M.D., Mette Stockner, M.D., Bernard Zinman, M.D., Richard M. Bergenstal, M.D., and John B. Buse, M.D., Ph.D. for the LEADER Steering Committee on behalf of the LEADER Trial Investigators

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.

Подробнее

1047

Зарубежные материалы

Diabetes with early kidney involvement may shorten life expectancy by 16 years

Дата публикации 22.10.2020
Автор: Chi Pang Wen, Chia Hsuin Chang, Min Kuang Tsai, June Han Lee, Po Jung Lu, Shan Pou Tsai, Christopher Wen, Chien Hua Chen, Chih Wen Kao, Chwen Keng Tsao and Xifeng Wu

This study aimed to identify the excess risks associated with diabetic patients with early kidney involvement (early diabetic kidney disease). The mortality risks of early diabetic kidney disease, defined as diabetes in early stages 1-3 chronic kidney disease (CKD), were assessed from a cohort of 512,700 adults in Taiwan participating in a health surveillance program from 1994-2008. Three related ...

Подробнее

1262

Зарубежные материалы

Eligibility Varies Among the 4 Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Outcomes Trials: Implications for the General Type 2 Diabetes US Population

Дата публикации 22.10.2020
Автор: Eric T. Wittbrodt, PharmD, MPH; James M. Eudicone, MS, MBA; Kelly F. Bell, PharmD, MSPhr; Devin M. Enhoffer, PharmD; Keith Latham, PharmD; and Jennifer B. Green, MD

In 2015, more than 23 million adults in the United States had a diagnosis of diabetes, with an estimated 95% of cases being type 2 diabetes (T2D). Patients with T2D are at increased risk of cardiovascular disease (CVD),2 and therefore, improvement of cardiovascular (CV) outcomes is a goal of diabetes management.3,4 Good glycemic control in T2D has been associated with a reduced risk of microvascul ...

Подробнее

836

БИБЛИОТЕКА